Payment overview · 2025
General Payments
$453.33
24 reported records · 10 companies
Healthcare provider profile · identity verified
Michael E. Taylor, MD
Allopathic & Osteopathic Physicians|Family Medicine · SUMMERSVILLE, WV · NPI 1770683203
Verified facts
What the public records show
CMS Open Payments records show Michael E. Taylor, MD received $453.33 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $176.79 | 39.0% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.76 | 16.5% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.83 | 9.7% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $42.97 | 9.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.82 | 5.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.13 | 4.9% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $21.36 | 4.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.37 | 3.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.29 | 3.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.01 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $453.33 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $74.31 | 5 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $66.07 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.51 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $42.97 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.39 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $31.86 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.25 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $28.25 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 69 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 941 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 762 | 184 |
| Atorvastatin Calcium | Atorvastatin Calcium | 754 | 197 |
| Losartan Potassium | Losartan Potassium | 620 | 170 |
| Metoprolol Succinate | Metoprolol Succinate | 611 | 168 |
| Omeprazole | Omeprazole | 596 | 156 |
| Gabapentin | Gabapentin | 585 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 547 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 511 | 136 |
| Alprazolam | Alprazolam | 478 | 66 |
| Montelukast Sodium | Montelukast Sodium | 440 | 113 |
| Tramadol Hcl | Tramadol Hcl | 414 | 74 |
| Furosemide | Furosemide | 376 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 376 | 107 |
| Tamsulosin Hcl | Tamsulosin Hcl | 375 | 95 |
| Meloxicam | Meloxicam | 371 | 94 |
| Lisinopril | Lisinopril | 362 | 105 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 298 | 37 |
| Prednisone | Prednisone | 298 | 151 |
| Clopidogrel | Clopidogrel Bisulfate | 295 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 288 | 67 |
| Metformin Hcl | Metformin Hcl | 285 | 70 |
| Eliquis | Apixaban | 283 | 61 |
| Lorazepam | Lorazepam | 280 | 43 |
| Simvastatin | Simvastatin | 278 | 69 |
| Duloxetine Hcl | Duloxetine Hcl | 273 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 260 | 62 |
| Potassium Chloride | Potassium Chloride | 256 | 81 |
| Metformin Hcl Er | Metformin Hcl | 255 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 225 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 63 |
| Trazodone Hcl | Trazodone Hcl | 209 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 208 | 54 |
| Clonazepam | Clonazepam | 195 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 190 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 190 | 45 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 188 | 53 |
| Atenolol | Atenolol | 172 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 56 |
| Diazepam | Diazepam | 158 | 17 |
| Buspirone Hcl | Buspirone Hcl | 154 | 36 |
| Famotidine | Famotidine | 152 | 38 |
| Glimepiride | Glimepiride | 151 | 38 |
| Amitriptyline Hcl | Amitriptyline Hcl | 146 | 33 |
| Pregabalin | Pregabalin | 146 | 22 |
| Bupropion Xl | Bupropion Hcl | 145 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 138 | 34 |
| Sertraline Hcl | Sertraline Hcl | 137 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 132 | 92 |
| Ibuprofen | Ibuprofen | 130 | 29 |
| Mounjaro | Tirzepatide | 128 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 127 | 101 |
| Methylprednisolone | Methylprednisolone | 125 | 103 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 121 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 27 |
| Donepezil Hcl | Donepezil Hcl | 118 | 28 |
| Spironolactone | Spironolactone | 118 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 116 | 32 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 111 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 111 | 20 |
| Xarelto | Rivaroxaban | 111 | 25 |
| Carvedilol | Carvedilol | 107 | 29 |
| Allopurinol | Allopurinol | 102 | 29 |
| Ozempic | Semaglutide | 99 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 97 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 96 | 16 |
| Azithromycin | Azithromycin | 95 | 68 |
| Naproxen | Naproxen | 91 | 21 |
| Baclofen | Baclofen | 90 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 22 |
| Warfarin Sodium | Warfarin Sodium | 89 | 15 |
| Ezetimibe | Ezetimibe | 86 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 19 |
| Mirtazapine | Mirtazapine | 85 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 83 | 20 |
| Ondansetron Odt | Ondansetron | 83 | 37 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 82 | 15 |
| Meclizine Hcl | Meclizine Hcl | 82 | 34 |
| Amoxicillin | Amoxicillin | 80 | 65 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 15 |
| Finasteride | Finasteride | 75 | 26 |
| Synthroid | Levothyroxine Sodium | 70 | 14 |
| Linzess | Linaclotide | 69 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 69 | suppressed |
| Celecoxib | Celecoxib | 67 | 17 |
| Lovastatin | Lovastatin | 67 | 19 |
| Fenofibrate | Fenofibrate | 65 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 19 |
| Carbamazepine | Carbamazepine | 64 | 15 |
| Propranolol Hcl | Propranolol Hcl | 64 | 11 |
| Clonidine Hcl | Clonidine Hcl | 63 | 19 |
| Promethazine Hcl | Promethazine Hcl | 63 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 11 |
| Fluconazole | Fluconazole | 60 | 33 |
| Trimethoprim | Trimethoprim | 60 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 59 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 18 |
| Topiramate | Topiramate | 56 | suppressed |
| Januvia | Sitagliptin Phosphate | 54 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 53 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 52 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 49 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | 17 |
| Nystatin | Nystatin | 49 | 20 |
| Torsemide | Torsemide | 49 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 48 | 11 |
| Jardiance | Empagliflozin | 47 | 15 |
| Aripiprazole | Aripiprazole | 46 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 12 |
| Nitroglycerin | Nitroglycerin | 43 | 28 |
| Clobetasol Propionate | Clobetasol Propionate | 42 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 41 | suppressed |
| Nifedipine Er | Nifedipine | 40 | 12 |
| Digoxin | Digoxin | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 38 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 19 |
| Valsartan | Valsartan | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 26 |
| Primidone | Primidone | 36 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Cephalexin | Cephalexin | 32 | 28 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Estradiol | Estradiol | 31 | 11 |
| Premarin | Estrogens, Conjugated | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Klor-Con M20 | Potassium Chloride | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 23 |
| Ramipril | Ramipril | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Colchicine | Colchicine | 28 | 14 |
| Fluocinonide | Fluocinonide | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 17 |
| Modafinil | Modafinil | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Etodolac | Etodolac | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Sulindac | Sulindac | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Metolazone | Metolazone | 23 | 14 |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 15 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 16 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Pentazocine-Naloxone Hcl | Pentazocine Hcl/Naloxone Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $453.33 · 24 records | ABBVIE INC. | AIRSUPRA, CREON, Dexcom G6 Transmitter, FREESTYLE LIBRE 2, GVOKE HYPOPEN, Korlym, LINZESS, Ohtuvayre, Ozempic, Paradise Ultrasound Renal Denervation System, QULIPTA, Rybelsus, SYNTHROID, UBRELVY, VOWST, Wegovy, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error